The Q3 2026 biotech funding tracker: a rebound that only the rich feel
Biotech venture dollars are up sharply — and almost all of the money went to a handful of AI-shaped names. The gap beneath the megadeals is the real story.
Dengue's hard year: how 2026 broke the vaccine field's momentum — and what happens now
Brazil suspended the world's first single-dose dengue vaccine after two deaths under investigation. Sanofi is exiting the market entirely. The US is about to have zero licensed dengue vaccines. Inside the most turbulent year in flavivirus history.
The archive in the attic: what this domain's first tenant knew about dengue twenty years early
Before it was a newsroom, hibiotech.com was the home of a Hawaiian dengue vaccine developer. Its press archive — 59 releases spanning 2002 to 2016 — reads like a rough draft of today's flavivirus headlines. We're restoring it.
Qdenga's long shadow: the world's most consequential vaccine that America won't touch
Takeda's two-dose shot is carrying national programs on four continents — while staying unapproved in the country that helped invent modern vaccinology. Why the gap is unlikely to close.
mRNA's second act arrives, and it looks like a flu shot
The FDA has approved the first mRNA influenza vaccine. The combo COVID-plus-flu jab data is next, and a bird-flu pandemic trial is already running. The technology's post-COVID chapter finally has product in it.
Why there's still no human West Nile vaccine — and the candidates closest to changing that
A quarter-century after the virus reached New York, horses have a vaccine and humans don't. The tracker of what's actually in trials.
Why Big Pharma is licensing earlier (and paying more)
Seven in ten recent deals happened at preclinical or phase 1 — capturing three quarters of upfront cash. The patent cliff has turned early-stage biology into a seller's market.
The first real verdicts are in for AI-discovered drugs
No AI-designed molecule has full FDA approval yet. But the first AI-native candidate has reached phase 3, the mid-stage data has started arriving, and the question has changed from 'how fast?' to 'do they work?'
Fill-finish: the bottleneck nobody wants to build
Lonza says the CDMO world doesn't have the capacity. Demand is booked years ahead. Inside the least glamorous constraint in biotech.
The platform premium, audited: what a $200M Series B actually buys
Isomorphic raised $2.1 billion without a marketed product. AI-native biotechs routinely clear nine figures pre-clinic. An audit of what the money purchases — and what evidence would justify it.
